PHVS

Company Overview — What Does Pharvaris N.V. Do?

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands. Pharvaris N.V. (PHVS) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Berndt A. E. Modig and employs approximately 30 people. With a market capitalization of $1.9B, PHVS is one of the notable companies in the Healthcare sector.

Pharvaris N.V. (PHVS) Stock Rating — Hold (April 2026)

As of April 2026, Pharvaris N.V. receives a Hold rating with a composite score of 42.3/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.PHVS ranks #646 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Pharvaris N.V. ranks #38 of 838 stocks, placing it in the top 10% of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

PHVS Stock Price and 52-Week Range

Pharvaris N.V. (PHVS) currently trades at $27.07. The 52-week high for PHVS is $29.80, which means the stock is currently trading -9.2% from its annual peak. The 52-week low is $11.51, putting the stock 135.2% above its annual trough. Recent trading volume was 0 shares, suggesting relatively thin trading activity.

Is PHVS Overvalued or Undervalued? — Valuation Analysis

Pharvaris N.V. (PHVS) carries a value factor score of 28/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 6.57x, versus the sector average of 2.75x. The price-to-sales ratio is 33.09x, compared to 1.66x for the average Healthcare stock.

At current multiples, Pharvaris N.V. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Pharvaris N.V. Profitability — ROE, Margins, and Quality Score

Pharvaris N.V. (PHVS) earns a quality factor score of 33/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -200.5%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -184.3% versus the sector average of -33.1%.

On a margin basis, Pharvaris N.V. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -996.1% (sector: -66.1%). Net profit margin stands at -1009.8%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

PHVS Debt, Balance Sheet, and Financial Health

Pharvaris N.V. has a debt-to-equity ratio of 0.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. Total debt on the balance sheet is $661,473. Cash and equivalents stand at $291M.

PHVS has a beta of 0.72, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Pharvaris N.V. is 53/100, reflecting average volatility within the normal range for its sector.

Pharvaris N.V. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Pharvaris N.V. reported revenue of $14M and earnings per share (EPS) of $-2.57. Net income for the quarter was $-139M. Gross margin was 100.0%. Operating income came in at $-137M.

In FY 2024, Pharvaris N.V. reported revenue of $14M and earnings per share (EPS) of $-2.57. Net income for the quarter was $-139M. Gross margin was 100.0%. Revenue grew 527.0% year-over-year compared to FY 2023. Operating income came in at $-137M.

In FY 2023, Pharvaris N.V. reported revenue of $-3M and earnings per share (EPS) of $-2.91. Net income for the quarter was $-112M. Revenue grew -127.2% year-over-year compared to FY 2022. Operating income came in at $-110M.

In FY 2022, Pharvaris N.V. reported revenue of $12M and earnings per share (EPS) of $-2.27. Net income for the quarter was $-82M. Gross margin was 100.0%. Revenue grew -8.9% year-over-year compared to FY 2021. Operating income came in at $-81M.

Over the past 7 quarters, Pharvaris N.V. has demonstrated a growth trajectory, with revenue expanding from $0 to $14M. Investors analyzing PHVS stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

PHVS Dividend Yield and Income Analysis

Pharvaris N.V. (PHVS) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

PHVS Momentum and Technical Analysis Profile

Pharvaris N.V. (PHVS) has a momentum factor score of 64/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 60/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 12/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

PHVS vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Pharvaris N.V. (PHVS) ranks #38 out of 838 stocks based on the Blank Capital composite score. This places PHVS in the top decile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing PHVS against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full PHVS vs S&P 500 (SPY) comparison to assess how Pharvaris N.V. stacks up against the broader market across all factor dimensions.

PHVS Next Earnings Date

No upcoming earnings date has been announced for Pharvaris N.V. (PHVS) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy PHVS? — Investment Thesis Summary

Pharvaris N.V. presents a balanced picture with arguments on both sides. The quality score of 33/100 flags below-average profitability. The value score of 28/100 indicates premium valuation. Price momentum is positive at 64/100, suggesting the trend favors buyers.

In summary, Pharvaris N.V. (PHVS) earns a Hold rating with a composite score of 42.3/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on PHVS stock.

Related Resources for PHVS Investors

Explore more research and tools: PHVS vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare PHVS head-to-head with peers: PHVS vs AZN, PHVS vs SLGL, PHVS vs VMD.